HSP90AB1 has been identified as a potential therapeutic target for metabolic diseases including diabetes, and suppression of HSP90AB1 is a valid therapeutic clinically relevant strategy in the management of dysregulated metabolic disease and insulin resistance [17]. Here, HSP90AB1 is linked to metabolic disease.